Education and Training
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
The purpose of this study is to further quantify the risk of cerebrovascular events (CVEs) following sipuleucel-T (PROVENGE®) therapy, and to follow all subjects for survival.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- biological: sipuleucel-T
Eligibility
Inclusion Criteria:
- subjects must be at least 18 years of age
- subjects with advanced prostate cancer who will receive sipuleucel-T or who underwent
their first leukapheresis for manufacture of sipuleucel-T ≤ 6 months prior to
enrollment
- subjects must understand and sign an informed consent form
Exclusion Criteria:
- none
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
Male
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Denise Haas
6507361252
Not Recruiting